https://www.biopharmawatch.com/news/STE/xodus-medical-acquired-by-steris BiopharmaWatch en 2026-10-12T18:43:00.000Z Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE) https://www.biopharmawatch.com/news/REGN/pasatru-demonstrates-zero-new-ho-lesions-fop BiopharmaWatch en 2026-10-12T16:06:00.000Z Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension https://www.biopharmawatch.com/news/SNY/sanofi-voting-rights-shares-september-2026 BiopharmaWatch en 2026-10-12T16:05:00.000Z Sanofi: Information concerning the total number of voting rights and shares – September 2026 https://www.biopharmawatch.com/news/BBNX/beta-bionics-securities-fraud-class-action-ilet-fda-compliance BiopharmaWatch en 2026-10-12T15:48:00.000Z Beta Bionics (NASDAQ: BBNX) Faces Securities Fraud Class Action Amid iLet FDA Compliance https://www.biopharmawatch.com/news/PIII/p3-health-partners-appoints-chief-clinical-officer BiopharmaWatch en 2026-10-12T13:05:00.000Z P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer https://www.biopharmawatch.com/news/SBC/sbc-medical-presentation-cantor-fitzgerald-forum BiopharmaWatch en 2026-10-12T13:00:00.000Z SBC Medical to Present at Cantor Fitzgerald Hong Kong’s Inaugural Asia Longevity Forum https://www.biopharmawatch.com/news/MDT/medtronic-minimed-exchange-offer-results BiopharmaWatch en 2026-10-12T12:45:00.000Z Medtronic Announces Preliminary Results of MiniMed Group, Inc. Exchange Offer https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-october-2026-investor-conferences BiopharmaWatch en 2026-10-12T12:30:00.000Z Citius Pharmaceuticals to Participate in October 2026 Investor Conferences https://www.biopharmawatch.com/news/NXGL/nexgel-reverse-stock-split-effectiveness BiopharmaWatch en 2026-10-12T12:30:00.000Z NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness https://www.biopharmawatch.com/news/PALI/palisade-bio-presents-phase-2-data-pali-2108-acg-2026 BiopharmaWatch en 2026-10-12T12:05:00.000Z Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026 https://www.biopharmawatch.com/news/EYE/national-vision-scholarship-2026-2027 BiopharmaWatch en 2026-10-12T12:04:00.000Z National Vision Launches 2026-2027 Scholarship Program, Exploring the Balance Between Innovation and Human Connection https://www.biopharmawatch.com/news/GERN/geron-imetelstat-presentations-hematology-congresses BiopharmaWatch en 2026-10-12T12:03:00.000Z Geron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and Asia https://www.biopharmawatch.com/news/OSCR/oscar-health-2026-q3-earnings-call BiopharmaWatch en 2026-10-12T12:01:00.000Z Oscar Health, Inc. 2026 Third Quarter Earnings Conference Call https://www.biopharmawatch.com/news/ARDX/ardelyx-acg-2026-ibsrela-healthcare-utilization BiopharmaWatch en 2026-10-12T12:01:00.000Z Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C https://www.biopharmawatch.com/news/GERN/imtelstat-lower-risk-mds-clinical-outcomes BiopharmaWatch en 2026-10-12T12:00:00.000Z October 12, 2026 https://www.biopharmawatch.com/news/MIRM/mirum-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-12T12:00:00.000Z Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-stk-002-adoa-aao-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting https://www.biopharmawatch.com/news/BHC/six-month-pilot-study-cirrhosis-clinical-pathway BiopharmaWatch en 2026-10-12T12:00:00.000Z Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-phase-2a-study-od-001-vedolizumab BiopharmaWatch en 2026-10-12T12:00:00.000Z Odyssey Therapeutics to Present Design of Phase 2a Study Evaluating OD-001 in Combination with Vedolizumab at ACG 2026 https://www.biopharmawatch.com/news/IMDX/imdx-participate-us-bancorp-btig-kidney-health-forum BiopharmaWatch en 2026-10-12T12:00:00.000Z iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings https://www.biopharmawatch.com/news/HUMA/humacyte-phase-3-v012-trial-results-asn-kidney-week-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/SYK/stryker-cmr-surgical-strategic-alliance-robotic-surgery BiopharmaWatch en 2026-10-12T12:00:00.000Z Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery https://www.biopharmawatch.com/news/PHAT/phathom-new-cost-effectiveness-data-voquezna-acg-2026 BiopharmaWatch en 2026-10-12T12:00:00.000Z Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026 https://www.biopharmawatch.com/news/STE/steris-acquires-xodus-medical-surgical-products BiopharmaWatch en 2026-10-12T12:00:00.000Z STERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participation-world-adc-conference BiopharmaWatch en 2026-10-12T12:00:00.000Z Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference https://www.biopharmawatch.com/news/CMND/clearmind-launches-automated-ev-charging-technology BiopharmaWatch en 2026-10-12T11:55:00.000Z Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets https://www.biopharmawatch.com/news/TGTX/tg-therapeutics-briumvi-ocrelizumab-ofatumumab-analysis BiopharmaWatch en 2026-10-12T11:30:00.000Z TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis https://www.biopharmawatch.com/news/CRVO/cervomed-presents-initial-results-phase-2a-trial-neflamapimod-nonfluent-variant BiopharmaWatch en 2026-10-12T11:30:00.000Z CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-poster-presentations-fall-dermatology-2026 BiopharmaWatch en 2026-10-12T11:30:00.000Z Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 https://www.biopharmawatch.com/news/NGEN/nervgen-first-participant-dosed-restore-phase-3-study BiopharmaWatch en 2026-10-12T11:15:00.000Z NervGen Announces First Participant Dosed in RESTORE, a Phase 3 Registrational Study Evaluating NVG-291 in Chronic Spinal Cord Injury https://www.biopharmawatch.com/news/RGNX/regenxbio-investor-event-surabgene-lomparvovec-wet-amd BiopharmaWatch en 2026-10-12T11:05:00.000Z REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 https://www.biopharmawatch.com/news/PODD/insulet-announces-omnipod-discover-release BiopharmaWatch en 2026-10-12T11:00:00.000Z Insulet Announces Omnipod Discover Now Available in U.S. https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-celiac-disease-results BiopharmaWatch en 2026-10-12T11:00:00.000Z First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease https://www.biopharmawatch.com/news/VANI/vivani-medical-investor-conferences-october-2026 BiopharmaWatch en 2026-10-12T11:00:00.000Z Vivani Medical Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-igg4-related-disease-data BiopharmaWatch en 2026-10-12T11:00:00.000Z Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-ceo-transition-growth BiopharmaWatch en 2026-10-12T11:00:00.000Z Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth https://www.biopharmawatch.com/news/IRIX/iridex-micropulse-technology-glaucoma-study BiopharmaWatch en 2026-10-12T11:00:00.000Z Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-jamie-harrell-appointment BiopharmaWatch en 2026-10-12T11:00:00.000Z Fate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies https://www.biopharmawatch.com/news/BMY/bms-positive-results-phase-3-action-1-ryz101 BiopharmaWatch en 2026-10-12T10:55:00.000Z Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-synchronocity-trial-results BiopharmaWatch en 2026-10-12T10:55:00.000Z ANI Pharmaceuticals Announces Positive Phase 4 Open-Label, Single-Arm SYNCHRONICITY Clinical Trial Results Presented as Late Breaking Oral Presentation at the American Academy of Ophthalmology 2026 Annual Meeting https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-phase-3-aloft-ipf-trial-admilparant BiopharmaWatch en 2026-10-12T10:50:00.000Z Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint https://www.biopharmawatch.com/news/BLCO/bausch-lomb-appoints-thomas-appio-ceo BiopharmaWatch en 2026-10-12T10:45:00.000Z Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance https://www.biopharmawatch.com/news/TFX/enrollment-completed-biomag-ll-clinical-study-tfx BiopharmaWatch en 2026-10-12T10:30:00.000Z Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261012 BiopharmaWatch en 2026-10-12T10:29:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/MNOV/medicinova-ceo-shareholder-update-phase-2-trial BiopharmaWatch en 2026-10-12T10:00:00.000Z MediciNova CEO Provides Shareholder Update https://www.biopharmawatch.com/news/BMY/global-patient-week-bms-ehtiwaa-small-wins BiopharmaWatch en 2026-10-12T08:10:00.000Z On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-12 BiopharmaWatch en 2026-10-12T07:15:20.465Z IGALMI PDUFA for Bipolar Disorders: Biotech Catalysts Oct 12, 2026 https://www.biopharmawatch.com/news/MEDS/humana-medicaid-coverage-chemofx-assay-gynecologic-cancers BiopharmaWatch en 2026-10-12T06:00:00.000Z DataMEDS SI Announces Helomics Receives Medicaid Coverage Policy For Chemofx(R) Assay In Gynecologic Cancers https://www.biopharmawatch.com/news/MIRM/mirum-investor-call-phase-3-expand-study-livmarli BiopharmaWatch en 2026-10-11T21:00:00.000Z Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-anb033-phase-1b-trial-data BiopharmaWatch en 2026-10-11T20:00:00.000Z First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 https://www.biopharmawatch.com/news/BBIO/acoramidis-improves-outcomes-vs-tafamidis-attr-cm BiopharmaWatch en 2026-10-11T18:30:00.000Z Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records https://www.biopharmawatch.com/news/FRNM/freenome-new-validation-data-crc-screening-test-acg-2026 BiopharmaWatch en 2026-10-11T17:00:00.000Z Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 https://www.biopharmawatch.com/news/BBIO/encaleret-phase-3-calibrate-trial-results BiopharmaWatch en 2026-10-11T15:42:00.000Z Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 https://www.biopharmawatch.com/news/MRK/merck-presents-one-year-results-pivotal-phase-2b-3-brunello BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026 https://www.biopharmawatch.com/news/MRK/merck-brunello-study-results-remigromig-dme BiopharmaWatch en 2026-10-10T22:10:00.000Z Merck Presents One-Year Results from the Pivotal Phase 2b/3 BRUNELLO Study Evaluating Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, in Adults with Diabetic Macular Edema at AAO 2026